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ADVANCES IN AMBULATORY OXYGEN WORKSHOP AND 
LONG-TERM OXYGEN THERAPY IN REAL-LIFE PRACTICE 
The practical workshop took place on Sunday 27th September 
2015 and the symposium took place on Monday 28th September 
2015, as part of the European Respiratory Society (ERS) 
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MEETING SUMMARY
The practical workshop presented recent advances in the field of ambulatory oxygen (AO), with experts 
discussing identification of patients who would benefit from AO, as well as current trials to measure 
specific benefits of AO in chronic patients. In particular, AO prescription in clinical practice and 
developments in pulsed-dose delivery of AO as a more efficient method of oxygen delivery were extensively 
discussed. After audience questions, the attendees had the opportunity to handle the AO systems on 
display in order to gain greater insight into their functionality and wearability, which should assist them in 
providing the most appropriate device for each patient.
The symposium addressed considerations required when prescribing long-term oxygen therapy (LTOT). Dr 
Kampelmacher reviewed current indications for LTOT, emphasising the importance of accurate assessment 
of patients for LTOT, optimisation of oxygen dose, and patient education. Dr Vivodtzev discussed the 
evidence for LTOT in patients with exercise-induced desaturation, the role of portable oxygen concentrators, 
and the optimisation necessary to benefit from their use. The symposium concluded with a health economic 
study presented by Dr Little, demonstrating the cost benefits of a reform of the Scottish healthcare oxygen 
supply service.
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PRACTICAL WORKSHOP
Advances in Ambulatory Oxygen 
Professor Enrico Clini 
Prof Clini opened the workshop by reviewing 
which patients should be given AO. The most 
recent guidelines recommend that AO should not 
be routinely prescribed for all patients needing 
stationary oxygen supplementation, but should 
be offered to improve walking and exercise within 
a pulmonary rehabilitation course, with muscle 
training encouraged in patients with reduced 
lung function.1
Patient selection is an important unresolved issue. 
Lung function measurements have some predictive 
value for low (FEV1 <50%) and high (FEV1 ≥80%) 
scores,2 but do not address those with intermediate 
scores, and there is variation in oxygen saturation 
between patients who have the same lung function. 
A scoring system for identifying patients at risk 
of walking-induced desaturation has recently 
been developed, which takes both resting oxygen 
saturation and lung function into account.3 However, 
the type of exercise used to test for exertional 
desaturation is also a contributory factor.4
The efficacy of LTOT for chronic obstructive 
pulmonary disease (COPD) patients who are 
normoxic at rest but who desaturate during physical 
activity was identified as an important issue for 
future research.5 In clinical practice, AO is often 
prescribed to patients outside of the guideline 
recommendations in order to enable them to 
carry out activities of daily living. While these 
patients report improved quality of life, such as 
reduced breathlessness and tiredness, AO does 
not appear to fully improve ability to exercise nor 
to increase survival.6 The functional limitations of 
theoxygen delivery system (e.g. portability of 
oxygen cylinders) may contribute to this, but 
providing AO to patients who will not benefit has 
cost implications both for patients and for the 
healthcare system. Current research includes 
the Long-term Oxygen Treatment Trial (LOTT, 
NCT00692198) study of the survival and quality-
of-life benefits of LTOT versus no LTOT in COPD 
patients who are normoxic at rest but who 
desaturate during exercise; results are yet to 
be reported. Results are also awaited from the 
OM-COPD trial (NCT01722370) investigating the 
physiological benefits of AO therapy in this COPD 
patient population.
Ambulatory Oxygen  
Prescription in Practice 
Doctor Daniel Veale 
As with any therapy, AO should be appropriately 
prescribed for each patient with precision, 
specifying the dose, frequency, and timing. There 
are many questions that need to be answered in 
order to define these parameters for AO. Reliability 
in the measurement of blood gas is needed, as well 
as a standard definition of the level of desaturation 
at which a patient should be given AO (currently 
there is variation between clinicians regarding which 
level should be considered significant).7 The oxygen 
dose may also be important given the potential for 
oxygen toxicity.
The cost of AO to the healthcare system (in the USA, 
for example, one million Americans are on LTOT 
at a cost of over $2 billion per year)8 necessitates 
that AO is only prescribed to patients who will 
benefit, and that oxygen is used efficiently. The 
key recommendations in prescribing effective and 
efficient oxygen therapy have been identified by the 
LTOT Consensus as: education of all stakeholders, 
technical optimisation of LTOT delivery systems, 
evaluation of optimal oxygen delivery in individual 
patients, and patient compliance with the therapy.
Patient compliance with LTOT can be influenced 
by disease severity, being prescribed oxygen for 
>15 hours, acceptance of treatment, availability of 
an ambulatory device, and patient education.9 The 
prescriber can address these factors by ensuring 
that the indication for the therapy is correct, that 
the patient is educated, and that there is good 
medical and technical follow-up in the use of their 
device. Negotiation with the patient to modify their 
lifestyle is also part of good prescribing practice.
Ideally, portable oxygen devices would be small, 
silent, easy to handle, validated, and tested. Trials 
comparing the XPO2 and SOLO2 pulsed-delivery 
systems with continuous-flow oxygen in patients 
with COPD showed no significant difference in the 
overall improvement in exercise ability (6-minute 
walk test [6MWT]), but there was significant 
variability in effectiveness between individual 
patients (Figure 1).10,11 Each prescription should thus 
be individualised and validated by an ambulatory 
walk test to determine the effective setting. While 
the XPO2 and SOLO2 portable concentrators were 
similar in clinical performance to continuous liquid 
oxygen, they gave patients more freedom of 
movement to continue physical and social activities.
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 The Use of Pulsed Dose in  
Ambulatory Oxygen 
Professor Joao Carlos Winck 
Pulsed-dose oxygen delivery is an ‘on-demand’ 
delivery system for low-concentration oxygen 
therapy12 that can provide the same oxygen 
saturation to patients at a much lower volume 
per minute than continuous-flow oxygen. Pulsed-
dose systems aim to increase the oxygen tank 
duration and battery life of the concentrator and 
allow adjustable oxygen delivery, as well as smaller, 
more wearable machines. Delivering the oxygen 
bolus early in inspiration provides patients with 
the same oxygen concentration as continuous-flow 
oxygen.13 In models of lung function, the fraction of 
inspired oxygen (FiO2) is affected by the interaction 
of the patient’s inspiratory flow pattern and flow 
from the oxygen source.13 With a constant flow of 
oxygen, it is estimated that the final third of inspired 
volume remains in ‘dead space’ and does not 
reach the alveolar region of the lungs to participate 
in gaseous exchange. With pulsed-dose delivery, 
triggered by the patient’s inspiratory effort, no 
anatomical reservoir is established and the FiO2 is 
not reduced.13
Figure 1: Oxygen saturation during 6-minute walk test (6MWT) with XPO2 pulsed-dose oxygen delivery 
(A) or SOLO2 pulsed-dose oxygen delivery (B) versus C100 continuous-flow oxygen delivery. 
Note the individual variation in results indicated by the error bars.
Reprint permission requested from Elsevier (Couillard A et al. Rev Mal Respir. 2010;27:1030-8).
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Pulsed-dose devices have varying characteristics, 
such as the minute volume delivered at different 
pulse frequencies or their oxygen delivery 
performance in normal and COPD-affected lung 
models,14 and their performance in clinical practice 
should be evaluated. Previous studies have shown 
that pulsed-dose oxygen during exercise can 
provide similar oxygen saturation to continuous 
flow,15 although a comparison of four different 
demand oxygen delivery systems found significant 
differences in performance, with better performance 
shown by the devices that delivered a bolus of 
oxygen at the onset of inspiration.16 
Several trials comparing pulsed-dose oxygen with 
continuous-flow oxygen have found comparable 
clinical efficacy, although patients preferred the 
portable devices.10,17,18 During exercise, a 3-fold 
increase in oxygen flow compared with resting levels 
is recommended.17 Clinical evaluation of different 
oxygen concentrators for preventing desaturation 
during the 6MWT in patients with COPD found 
differences in performance,19 which reinforces the 
recommendation for evaluating efficacy of the 
individual patient’s prescription.
Fewer studies have been performed on the efficacy 
of nocturnal pulsed-dose oxygen delivery in 
patients with COPD and nocturnal hypoxaemia. 
An early comparison found on-demand oxygen 
delivery was comparable to continuous-flow 
oxygen in the majority of patients,20 which was 
confirmed by a more recent study using a portable 
concentrator.21 A Spanish study comparing the 
use of a single portable pulsed-dose device 
with combined use of stationary and portable 
oxygen delivery in patients with COPD found that 
patients preferred using the single pulsed-dose 
device, but also found that hypoxaemia was 
more frequent with a single device, especially at 
night.22 Individual patient titration of settings, 
using an oximeter to evaluate oxygen saturation, 
would be recommended for nocturnal use, 
although there are not sufficient data at present 
to make recommendations for calibration of night- 
time oxygen delivery with pulsed-dose devices.
In a study simulating air travel, comparison of 
the performance of several pulsed-dose oxygen 
delivery devices found that patients needed to use 
the maximum settings in order to maintain oxygen 
saturation, which rapidly drained the batteries.23 
While the portability of pulsed-dose oxygen delivery 
can make travel easier for people with COPD, 
these findings are useful to take into account when 
considering air travel (Figure 2). 
Q&A session
Could the panel comment on progress with oximeter-
controlled pulsed-dose oxygen flow system devices? 
Prof Winck answered that there is only one system 
commercially available at present, but that the 
technology would be developed more widely as 
oximeter control made good sense. For clinicians, it 
made evaluation of efficacy and trialling the device’s 
performance in patients much easier. 
Is it important for the patient to be in a stable state 
before starting LTOT? Or can it be started while the 
patient is still in an exacerbated state, before they 
leave hospital?
Prof Veale answered that the recommendation for 
patients to start LTOT when stable is due to the 
original trials of LTOT, which were carried out in 
patients who were stable. He felt that it was worth 
giving LTOT to patients during exacerbations and 
in hospital.
Figure 2: Following the audience questions, attendees were invited to a hands-on demonstration of 
ambulatory oxygen delivery devices.
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MINI SYMPOSIUM
Long-Term Oxygen Therapy in Real-Life 
Practice: Introduction 
Professor Jean-François Muir 
LTOT has entered a new era as a result of 
technological developments such as portable 
oxygen concentrators, concentrator-compressors, 
and, in the future, concentrator-liquefiers. The 
smaller size of these oxygen delivery systems can 
improve patients’ mobility and quality of life. Recent 
recommendations by the French government 
specified the type of equipment that should 
be prescribed for a patient’s particular oxygen 
needs,24 which have resulted in increased use of 
portable oxygen concentrators and decreased use 
of liquid oxygen tanks, with reduced costs to the 
healthcare system.
Current Indications of Long-Term 
Oxygen Therapy 
Doctor Mike Kampelmacher 
Dr Kampelmacher discussed current guidelines 
for prescribing LTOT1 to identify which patients 
will benefit from which type of oxygen therapy. 
Oxygen therapy is prescribed for hypoxaemia, 
defined as resting daytime PaO2 ≤7.3 kPa,
1 and not 
for breathlessness alone, as there is no evidence 
that oxygen improves breathlessness. Hypoxaemia 
can be measured most easily by pulse oximeters, 
but more accurately by arterial blood gas (ABG) 
measurements; pulse oximetry alone should not be 
used to assess patients for LTOT prescription.1
When prescribing oxygen, clinicians should be 
aware of, and educate patients about, the risks of 
fire (especially among patients who smoke), 
explosion, and freezing with gaseous and liquid 
oxygen, as well as the possibility of toxicity, if FiO2 
is greater than 0.4, and hypercapnia.25,26 However, 
hypercapnia should not prevent the treatment 
of hypoxaemia.
The prescription of LTOT is indicated to improve 
oxygenation in patients who have been given 
short-term oxygen therapy to treat hypoxaemia, 
or electively in patients with persistent low 
oxygenation.1 The assessment for LTOT is by ABG 
measurement in the absence of supplemental 
oxygen in patients who have been clinically 
stable for around 8 weeks since their last 
exacerbation. Patients should be reassessed and 
informed that their LTOT may be discontinued 
if blood gas assessments show clinical 
improvement.1 In some cases, LTOT is also indicated 
in patients with exercise-induced hypoxaemia or 
nocturnal hypoxaemia.
The Nocturnal Oxygen Therapy Trial (NOTT) and 
Medical Research Council trials in patients with 
COPD or chronic bronchitis and emphysema, 
respectively, showed significantly increased survival 
in the LTOT arms.27,28 The hypoxaemia indications 
for prescribing LTOT are based on these trials, 
with subsequent studies confirming the survival 
benefit of LTOT given for at least 15 hours per 
day.29 The evidence for other benefits, such as 
reduced pulmonary vascular resistance, reduced 
haematocrit, reduced hospital admissions, improved 
quality of life, improved exercise tolerance, and 
improved neurophysiological functioning, is not as 
robust due to being based on smaller studies.
When prescribing LTOT, clear instructions should 
be given to patients regarding the aims and 
effects of the treatment and the potential 
complications and dangers, and a follow-up visit 
by a specialist nurse should be carried out within 
4 weeks of initiating therapy. The oxygen flow 
rate should aim to give patients PaO2 levels of 
8.0–9.3 kPa or SaO2 levels >90%, achieved by 
pulse oximetry titration. Ambulatory and nocturnal 
oximetry may be performed to allow more 
accurate flow rates to be prescribed for exercise 
and sleep, respectively,29 as some patients who 
are adequately oxygenated during the day may 
become desaturated during sleep.30 Home oxygen 
therapy can be withdrawn from patients who 
smoke if the risks are considered to be too high.27 
Furthermore, there is evidence that patients 
who continue to smoke while on LTOT may have 
worse survival.31
Prescription of LTOT for moderate hypoxaemia 
is not indicated in the British Thoracic Society 
guidelines, as there is no evidence for a survival 
benefit. A recent study, the National Emphysema 
Treatment Trial, suggested that LTOT may 
be associated with worse survival in patients 
with moderate hypoxaemia.32 The LOTT study 
aims to determine the effect on mortality and 
hospitalisation in patients with COPD and moderate 
resting hypoxaemia, or normoxia and exercise-
induced desaturation, with results expected 
during 2015.33
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Long-Term Oxygen Therapy  
During Exercise 
Doctor Isabelle Vivodtzev 
Providing AO to those with chronic respiratory 
failure allows patients to exercise without 
becoming hypoxaemic, and exercise is a key part 
of pulmonary rehabilitation in patients with COPD. 
Currently, there is some debate as to whether 
normoxic patients who only desaturate during 
exercise should be given LTOT.1,34
It has been shown that AO improves quality of life 
in patients with COPD.35 Initial portable oxygen 
delivery devices (liquid or gaseous oxygen) 
had drawbacks to their use, in particular the 
dependence on a delivery service.36 Pulsed-dose 
delivery devices were developed in order to reduce 
oxygen requirements and improve portability, and 
demonstrated similar performance to continuous-
flow in patients at rest.37 However, the clinical 
efficiency of pulsed-dose oxygen delivery devices 
versus continuous-flow oxygen during exercise is 
controversial.38 The portable oxygen concentrator 
is an alternative technological development, which 
has potential advantages for AO in that it is free 
of the constraints of a delivered oxygen supply, 
has fewer safety risks, costs less, and could offer 
the patient more autonomy during travel. However, 
a study comparing devices found that the 
efficacy appeared to vary depending on the 
disease pathology (COPD or interstitial lung 
disease), ventilatory patterns were different 
between pulsed-dose and continuous-flow, and 
there were technological and technical differences in 
performance between devices. Crucially, the bolus 
of oxygen delivered was often chosen arbitrarily 
and not adjusted during exercise.39
Initial portable oxygen concentrators have 
undergone recent improvements to give more 
efficient and robust devices. Larger concentrators 
for autonomous home-based filling now provide 
further choice to patients. Tests of new oxygen 
concentrators show equivalent clinical efficacy 
between pulsed-dose delivery of liquid oxygen and 
pulsed-dose delivery from an oxygen concentrator 
in exercise tests. However, the wide variation seen 
between individual patients necessitates titration 
of the dose,10 and clinical studies are needed to 
identify more precise methods of titration with 
pulsed-dose delivery.
AO provision needs to be tailored to patients’ needs, 
including their level of activity.40 Recent French 
recommendations are for liquid oxygen only in 
active patients needing more than 3 L/min 
oxygen, whereas portable or transportable oxygen 
concentrators are recommended for less active 
patients who need less than this amount. The range 
of portable oxygen concentrators now available 
makes it possible to suit the device to the patient’s 
needs for autonomy, their level of activity, and their 
level of hypoxaemia.
Health Economic Aspects of Long-Term 
Oxygen Therapy 
Doctor Stuart Little 
Dr Little presented preliminary findings from a 
health economic study of the HomeFill oxygen 
concentrator system in the Scottish health service. 
The region studied, Dumfries and Galloway, was 
a largely rural, sparsely populated area where 
patients were often remote from healthcare 
resources. Originally, the system for oxygen 
provision was a mixture of hospitals with a national 
oxygen provision service, and primary care and 
community pharmacies with private provision 
of oxygen delivery devices. In primary care, 
inappropriate oxygen prescription (e.g. for 
breathlessness only) was an issue. 
An exploratory study (n=22) of oxygen-conserving, 
pulsed-dose delivery devices in the Dumfries and 
Galloway region showed a clear increase (40%) in 
time spent outside the home and a 50% reduction 
in oxygen cylinders used, thus providing quality-of- 
life benefits and financial savings. Another small 
study (n=20) of the HomeFill oxygen concentrator 
system in the same region found it to be very 
popular with patients, who reported increased 
freedom and confidence and decreased concern 
about supply. The cost reduction to the healthcare 
system, including reduction in transport and fuel 
costs, was estimated at 77%.41
In 2013, the National Oxygen Project was 
established in Scotland to provide a nationally 
coordinated service with a contracted service 
provider, instead of the previous pharmacy-led, 
regionally organised system, offering both pre-filled 
oxygen cylinders and home refillable cylinders (the 
HomeFill system). This was a more robust system, 
developed to be more cost-effective, and involved 
clinicians to ensure a patient-centred service. The 
reform included development of a single, consistent 
care pathway. The National Oxygen Project aimed 
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